(3-(diethylamino)phenyl)methanol | 58293-93-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-(diethylamino)phenyl)methanol
• 英文别名: [3-(Diethylamino)phenyl]methanol
• CAS: 58293-93-9
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: ZPYKUNKNLHBYDF-UHFFFAOYSA-N

物化性质

• 沸点：
  135 °C(Press: 3 Torr)
• 密度：
  1.028±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-(diethylamino)phenyl)methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以98%的产率得到3-(N,N-diethylamino)benzyl chloride
  参考文献：
  名称：

  Structurally Simple Benzyl-Type Photolabile Protecting Groups for Direct Release of Alcohols and Carboxylic Acids

  摘要：

  Structurally simple benzyl-type photolabile protecting groups (PPGs) have been developed to release alcohols and carboxylic acids. Release of two substrates from one PPG chromophore has also been accomplished.

  DOI：

  10.1021/acs.orglett.5b00699
• 作为产物：
  描述：

  3-(N,N-diethylamino)benzyl chloride 在 四丁基溴化铵 、 水 、 sodium hydride 、 乙腈 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 17.25h， 生成 (3-(diethylamino)phenyl)methanol
  参考文献：
  名称：

  Structurally Simple Benzyl-Type Photolabile Protecting Groups for Direct Release of Alcohols and Carboxylic Acids

  摘要：

  Structurally simple benzyl-type photolabile protecting groups (PPGs) have been developed to release alcohols and carboxylic acids. Release of two substrates from one PPG chromophore has also been accomplished.

  DOI：

  10.1021/acs.orglett.5b00699

文献信息

• N-imidaxo[1,2-b]pyridazinyl carbamates
  申请人：Burroughs Wellcome Co.

  公开号：US05091531A1

  公开（公告）日：1992-02-25

  Compounds of general formula (I) ##STR1## wherein R.sup.1 represents an optinally substituted carbocyclic or heterocyclic aryl group, or an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R.sup.2 represents an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group or an optionally substituted carbocyclic or heterocyclic aryl or aralkyl group; R.sup.3 represents a hydrogen atom or an alkyl group; and either X represents an oxygen or sulphur atom, a group --CH.sub.2 -- or a group NR.sup.4 where R.sup.4 represents a hydrogen atom or a C.sub.1-4 alkyl group; and Y represents a group --CH.sub.2 -- or --CH.sub.2 CH.sub.2 -- X-Y together represent the group --CH.dbd.CH--; and salts and physiologically functional derivatives thereof are useful in the treatment of tumours. Processes for preparing the compounds, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in the treatment of tumours are also described.

  通式（I）的化合物##STR1##其中R.sup.1代表一个可选择地取代的碳环或杂环芳基，或一个可选择地取代的烷基，烯基，环烷基或环烯基；R.sup.2代表一个可选择地取代的烷基，烯基，炔基，环烷基或环烯基，或一个可选择地取代的碳环或杂环芳基或芳基烷基；R.sup.3代表一个氢原子或一个烷基；X代表一个氧或硫原子，一个基团--CH.sub.2--或一个基团NR.sup.4，其中R.sup.4代表一个氢原子或一个C.sub.1-4烷基；Y代表一个基团--CH.sub.2--或--CH.sub.2 CH.sub.2-- X-Y一起代表羰基-CH.dbd.CH-；以及它们的盐和生理功能衍生物在肿瘤治疗中是有用的。还描述了制备这些化合物的方法，用于制备的中间体，含有它们的药物组合物以及它们在肿瘤治疗中的用途。
• A New Photocage Derived from Fluorene
  作者：Matiss Reinfelds、Jan von Cosel、Konstantin Falahati、Carsten Hamerla、Tomáš Slanina、Irene Burghardt、Alexander Heckel

  DOI：10.1002/chem.201802390

  日期：2018.9.3

  aromatic ring resulted in improved spectral properties. A systematic trend relating the electronic (π‐donor or acceptor) properties of the new aryl substituent and its position in the DEAMb ring to changes in the spectral properties could be observed. Conclusions from the experimental results were supported by computations obtained by using time‐dependent DFT. A second generation of DEAMb‐based photocages

  光不稳定的保护基（PPG或光笼）越来越受分子设计的考验，以满足诸如可见光谱范围内的吸光度，高摩尔吸收系数和离去基团释放的高量子产率之类的要求。对于有前途的3-二乙氨基苄基（DEAMb）光笼，这些性质的改进，其光活性基于Zimmerman meta效果，有报道。具有第二芳族环的芳族体系的膨胀导致改善的光谱性质。可以观察到系统的趋势，该趋势将新的芳基取代基的电子（π供体或受体）性质及其在DEAMb环中的位置与光谱性质的变化联系起来。从实验结果得出的结论得到了使用依赖时间的DFT进行的计算的支持。设计了第二代基于DEAMb的光笼。引入刚性连接体以通过限制旋转自由度确保芳环π系统更有效的缀合。所得的以芴醇（9-羟基芴）为基础的光笼具有比简单联苯系统更好的光谱特性。达到的最佳开卷截面为5320  m -1 厘米-1（εΦ 365）。
• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Yoshida Tomohiro

  公开号：US20100228026A1

  公开（公告）日：2010-09-09

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT 2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  该发明提供了一种磺酰基马隆酰胺衍生物，或其药理学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，对各种疾病具有治疗和/或预防作用，并且作为用于治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物剂形具有用处。
• Imidazo(1,2-b)pyridazine derivatives
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0305093A1

  公开（公告）日：1989-03-01

  Compounds of general formula (I) wherein R1 represents an optionally substituted carbocyclic or heterocyclic aryl group, or an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R2 represents an optionally substituted alkyl, alkenyl, alkynyl, cycloakyl or cycloalkenyl group or an optionally substituted carbocyclic or heterocyclic aryl or . aralkyl group; R3 represents a hydrogen atom or an alkyl group; and either X represents an oxygen or sulphur atom, a group -CH2- or a group NR4 where R4 represents a hydrogen atom or a C1-4 alkyl group; and Y represents a group -CH2- or -CH2CH2- or X-Y together represent the group -CH = CH-; and salts and physiologically functional derivatives thereof are useful in the treatment of tumours. Processes for preparing the compounds, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in the treatment of tumours are also described.

  通式(I)化合物 其中 R1 代表任选取代的碳环或杂环芳基，或任选取代的烷基、烯基、环烷基或环烯基； R2 代表任选取代的烷基、烯基、炔基、环烷基或环烯基，或任选取代的碳环或杂环芳基或.R3代表氢原子或烷基；X代表氧原子或硫原子、基团-CH2-或基团NR4，其中R4代表氢原子或C1-4烷基；Y代表基团-CH2-或-CH2CH2-或X-Y共同代表基团-CH＝CH-；其盐和生理功能衍生物可用于治疗肿瘤。此外，还描述了制备这些化合物的工艺、用于制备这些化合物的中间体、含有这些化合物的药物组合物以及它们在治疗肿瘤中的用途。
• NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1048666A1

  公开（公告）日：2000-11-02

  Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same; drugs characterized by containing at least one of these compounds as the active ingredient, in particular, preventives and/or remedies for pulmonary hypertension, ischemic heart diseases, erectile insufficiency, female sexual dysfunction or diseases against which cGMP-PDE inhibitory effects are efficacious and intermediates useful in producing the above compounds.

  新型融合四环杂环化合物，具有抑制环 GMP 磷酸二酯酶（cGMP-PDE）的强效和高选择性作用，且安全性高；其生产工艺；以含有至少一种上述化合物作为活性成分为特征的药物，特别是肺动脉高压、缺血性心脏病、勃起功能障碍、女性性功能障碍或 cGMP-PDE 抑制作用有效的疾病的预防和/或治疗药物，以及用于生产上述化合物的中间体。